Trophoblast cell-surface antigen 2 expression in digestive neoplasms: a promising target for antibody-drug conjugates
Trop2 is a promising biomarker for tumor aggressiveness and a potential target for antibody-drug conjugates (ADCs) in digestive cancers, particularly in SRCC-rich, metastatic, and invasive subtypes. These findings provide strong rationale for stratifying patient populations in future clinical investigations of Trop2-directed ADC therapies.
Authors
- Jinru Yang (ORCID: https://orcid.org/0000-0002-8838-5587)
- Fang‐Yuan Zhang (ORCID: https://orcid.org/0000-0002-1551-6048)
- Zixuan Ding
- Xing Cai
- Hong Qiu (ORCID: https://orcid.org/0009-0003-2480-6332)
- Conghua Xie
Institutions
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Wuhan Union Hospital (CN)
- Tongji Hospital (CN)
- Hubei Cancer Hospital (CN)
- First Hospital of Lanzhou University (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1093/oncolo/oyaf320
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
- Tongji University
- Wu Jieping Medical Foundation